Press Releases
Mylan NV Launches First Generic Doryx Delayed-Release Tablets, 200 mg
Mylan N.V. announced the U.S. launch of Doxycycline Hyclate Delayed-Release (DR) Tablets USP, 200 mg, a generic version of Mayne's Doryx®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental...
Press Releases
Gather China & World Pharmaceutical Entrepreneurs,Create a New Chapter of Chinese Pharma Industry
CPhI& P-MEC China will be held in Shanghai New International Expo Center on June 21-23, 2016.Bearing 15-year trust of the industry, CPhI& P-MEC China continuously lead the development of the Chinese pharmaceuticalindustry, and construct a global one-stop pharmaceutical industrial...
Press Releases
Kyowa Hakko Kirin Announces Commencement of Phase 2 Clinical Study of RTA 402 in CKD patients with type 2 diabetes in Japan
Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal Function by Inulin Clearance in a Phase II Clinical Study in Japan Kyowa Hakko Kirin Co., Ltd. (Tokyo; 4151 President and CEO: Nobuo Hanai; “Kyowa Hakko Kirin”). ...
Press Releases
CHAMPIX European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
Pfizer Inc announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX® (varenicline) have been updated to include safety and efficacy data from the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial....
Press Releases
Allergan Launches IBS-D on Tract, New Online Resource to Support Patients with Irritable Bowel Syndrome with Diarrhea
IBSDonTract.com provides clear information, symptom management strategies and interactive tools for people with IBS-D, which affects up to 15 million adults in the U.S.Allergan plc launched IBSDonTract.com, an online resource for those living with irritable bowel syndrome with diarrhea...
Press Releases
Pfizer Inc Announces EMA acceptance for Trumenba (Meningococcal Group B Vaccine) marketing authorization application review
Pfizer Inc announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused...
Press Releases
AbbVies Inc Leadership in Gastroenterology Showcased at Digestive Disease Week with New HUMIRA Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data
Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients. Late-breaking Phase 2 data evaluates risankizumab, an anti-IL-23 monoclonal biologic antibody for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















